JP2009107956A - アディポネクチン分泌促進及び/又は減少抑制剤 - Google Patents
アディポネクチン分泌促進及び/又は減少抑制剤 Download PDFInfo
- Publication number
- JP2009107956A JP2009107956A JP2007280195A JP2007280195A JP2009107956A JP 2009107956 A JP2009107956 A JP 2009107956A JP 2007280195 A JP2007280195 A JP 2007280195A JP 2007280195 A JP2007280195 A JP 2007280195A JP 2009107956 A JP2009107956 A JP 2009107956A
- Authority
- JP
- Japan
- Prior art keywords
- adiponectin
- culture supernatant
- promoting
- lactobacillus gasseri
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000011690 Adiponectin Human genes 0.000 title claims abstract description 60
- 108010076365 Adiponectin Proteins 0.000 title claims abstract description 60
- 230000028327 secretion Effects 0.000 title claims abstract description 45
- 230000001737 promoting effect Effects 0.000 title claims abstract description 34
- 230000009467 reduction Effects 0.000 title abstract description 7
- 239000012228 culture supernatant Substances 0.000 claims abstract description 53
- 241000186606 Lactobacillus gasseri Species 0.000 claims abstract description 38
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 27
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 14
- 239000005862 Whey Substances 0.000 description 13
- 102000007544 Whey Proteins Human genes 0.000 description 13
- 108010046377 Whey Proteins Proteins 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 8
- 235000020183 skimmed milk Nutrition 0.000 description 8
- 235000013618 yogurt Nutrition 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- 208000001145 Metabolic Syndrome Diseases 0.000 description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000001596 intra-abdominal fat Anatomy 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 102000014171 Milk Proteins Human genes 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000015140 cultured milk Nutrition 0.000 description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 4
- 239000002612 dispersion medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000021239 milk protein Nutrition 0.000 description 4
- 235000013923 monosodium glutamate Nutrition 0.000 description 4
- 229940073490 sodium glutamate Drugs 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000018773 low birth weight Diseases 0.000 description 1
- 231100000533 low birth weight Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Physiology (AREA)
- Sustainable Development (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【解決手段】ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055 (FERM P-15535)の培養上清を有効成分とするアディポネクチン分泌促進及び/又は減少抑制剤、アディポネクチン分泌促進及び/又は減少抑制用飲食品ならびに飼料。
【選択図】なし
Description
内臓脂肪組織は、アディポネクチン、プラスミノーゲンアクチベーターインヒビター、腫瘍壊死因子(TNF−α)、レプチン等の内分泌因子を分泌し、生体のホメオスタシスの維持に寄与している。しかし、脂肪細胞が肥大すると、これらの因子の分泌に異常を来たし、過剰、あるいは過小に分泌されるようになる。このバランスの破綻が、メタボリックシンドロームの発症や増悪に深く関与していることが、近年の研究から明らかになってきた。中でも、アディポネクチンの分泌異常がもっとも大きく影響していると考えられている(例えば非特許文献1参照)。
本発明者らは、乳酸菌熟成チーズから分離した乳たんぱく質由来のペプチドがアディポネクチン産生促進効果を有することを見出した(例えば特許文献6参照)。また、本出願人は、脱脂乳培地を用いた乳酸菌培養物、特にラクトバチラス・ガセリ(Lactobacillus gasseri)およびラクトバチラス・ヘルベチカス(Lactobacillus helveticus)の培養物に、血中アディポネクチン濃度増加促進及び/又は減少抑制効果があることを見出した(特願2006−244377号)。
(1)ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055 (FERM P-15535)の培養上清を有効成分とするアディポネクチン分泌促進及び/又は減少抑制剤。
(2)ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055 (FERM P-15535)の培養上清を有効成分とするアディポネクチン分泌促進及び/又は減少抑制用飲食品。
(3)ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055 (FERM P-15535)の培養上清を有効成分とするアディポネクチン分泌促進及び/又は減少抑制用飼料。
還元ホエイ培地(13重量%ホエイ粉、0.5重量%酵母エキス含有)を95℃で30分間殺菌した後、ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055を接種し、37℃で16時間培養し、得られた培養物を3,500回転で20分間遠心して、沈殿物を除いた培養上清を得た。これは、そのまま本発明のアディポネクチン分泌促進及び/又は減少抑制剤として使用し得る。
還元脱脂乳培地(13重量%脱脂粉乳、0.5重量%酵母エキス含有)を95℃で30分間殺菌した後、ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055を接種し、37℃で16時間培養し、得られた培養物を3,500回転で20分間遠心して、沈殿物を除いた培養上清を得た。これは、そのまま本発明のアディポネクチン分泌促進及び/又は減少抑制剤として使用し得る。
(脂肪細胞投与実験)
実施例1で得られた培養上清について、初代培養内臓脂肪細胞への投与実験を行った。
ラットの初代培養内臓脂肪細胞(VAC01、セルガレージ社)及び内臓脂肪細胞分化誘導培地(セルガレージ社)を用いて実験を行った。セルガレージ社のプロトコルに従って凍結保存した細胞を融解し、24穴プレートに播種した日をday0とし、アディポネクチン分泌が活発になるday5に、還元ホエイ培地培養上清を培地中に添加した。比較対照として、脂肪細胞分化誘導培地のみで何も添加しないものを用意した。37℃、二酸化炭素分圧0.5%の条件下で、細胞を2時間培養し、培地を回収した。
培地中に分泌されたアディポネクチン濃度の測定は、アディポネクチンELISAキット(大塚製薬社)を用いた。測定結果は、各ウエルから抽出したDNA量で標準化した。
ラクトバチラス・ガセリ(Lactobacillus gasseri)の培地に還元ホエイ培地を用いた場合のアディポネクチン濃度の測定結果を図1に示す。脂肪細胞に、ラクトバチラス・ガセリ(Lactobacillus gasseri)の培養上清を添加すると、何も投与しない細胞に比べて、アディポネクチン分泌量は約1.44倍に増加した。還元ホエイ培地のみを添加した細胞に比べると、アディポネクチン分泌量は約1.36倍に増加した。
還元ホエイ培地(13重量%ホエイ粉、0.5重量%酵母エキス配合)を95℃で30分間殺菌した後、ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055を接種し、37℃で16時間培養し、得られた培養物を3,500回転で20分間遠心して、沈殿物を除いた培養上清を得た。これを凍結乾燥処理して培養上清粉末を得た。この培養上清粉末1部に脱脂粉乳4部を混合し、この混合粉末を打錠機により1gずつ常法により打錠して、本発明のラクトバチラス・ガセリ(Lactobacillus gasseri)の培養上清200mgを含むアディポネクチン分泌促進及び/又は減少抑制錠剤を調製した。
ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055を還元ホエイ培地5Lに接種後、37℃、18時間静置培養を行った。培養終了後、7,000回転で15分間遠心して、沈殿物を除いた培養上清を得た。次いで、この培養上清を、脱脂粉乳10重量%、グルタミン酸ソーダ1重量%を配合した分散媒と同量混合し、pH7に調整後、凍結乾燥を行った。得られた凍結乾燥物を60メッシュのフルイで整粒化し、培養上清凍結乾燥物を製造した。第13改正日本薬局方解説書製剤総則「散剤」の規定に準拠し、この培養上清凍結乾燥物1gにラクトース(日局)400g、バレイショデンプン(日局)600gを加えて均一に混合し、本発明のアディポネクチン分泌促進及び/又は減少抑制剤を得た。
ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055を還元ホエイ培地5Lに接種後、37℃、18時間静置培養を行った。培養終了後、7,000回転で15分間遠心して、沈殿物を除いた培養上清を得た。次いで、この培養上清を、脱脂粉乳10重量%、グルタミン酸ソーダ1重量%を配合した分散媒と同量混合し、pH7に調整後、凍結乾燥を行った。得られた凍結乾燥物を60メッシュのフルイで整粒化し、培養上清凍結乾燥物を製造した。表1に示した配合により原料を混合し、造粒した後、カプセルに充填して、本発明のアディポネクチン分泌促進及び/又は減少抑制用カプセル剤を製造した。
ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055をMRS液体培地(Difco社)5Lに接種後、37℃、18時間静置培養を行った。培養終了後、7,000回転で15分間遠心して、沈殿物を除いた培養上清を得た。次いで、この培養上清を、脱脂粉乳10重量%、グルタミン酸ソーダ1重量%を配合した分散媒と同量混合し、pH7に調整後、凍結乾燥を行った。得られた凍結乾燥物を60メッシュのフルイで整粒化し、培養上清凍結乾燥物を製造した。このラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055の培養上清物粉末30gに、ビタミンCとクエン酸の等量混合物40g、グラニュー糖100g、コーンスターチと乳糖の等量混合物60gを加えて混合した。混合物をスティック状袋に詰め、本発明のアディポネクチン分泌促進及び/又は減少抑制用スティック状健康食品を製造した。
ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055を還元ホエイ培地5Lに接種後、37℃、18時間静置培養を行った。培養終了後、7,000回転で15分間遠心分離して、沈殿物を除いた培養上清を得た。表2に示した配合により原料を混合し、容器に充填した後、加熱殺菌して、本発明のアディポネクチン分泌促進及び/又は減少抑制用飲料を製造した。
ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055をMRS液体培地(Difco社)にて培養した。対数増殖期にある各培養液を、0.5%の酵母エキスを添加した13%還元ホエイ培地(115℃、20分滅菌)に1%接種し、マザーカルチャーを作成した。得られた培養物を3,500回転で20分間遠心して、沈殿物を除いた培養上清を得た。
100℃にて10分間加熱して冷却したヨーグルトミックスに得られた培養上清を2.5%添加後、ラクトバチラス・ブルガリカス(Lactobacillus bulgaricus)ストレプトコッカス・サーモフィラス(Streptococcus thermophilus)からなる混合スターター3%を添加して、37℃で発酵を行い、乳酸酸度0.85に到達した時点で冷却し、発酵を終了させ、本発明のアディポネクチン分泌促進及び/又は減少抑制用ヨーグルトを得た。
実施例8で得られたヨーグルト43kgにグラニュー糖4kg、水3kg、ペクチン0.15kgを加えた後に均質化して、本発明のアディポネクチン分泌促進及び/又は減少抑制用ドリンクヨーグルト50kgを得た。このドリンクヨーグルトはマイルドな好ましい風味を有し、pH3.6であった。
ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055をMRS液体培地(Difco社)5Lに接種後、37℃、18時間静置培養を行った。培養終了後、7,000回転で15分間遠心して、沈殿物を除いた培養上清を得た。次いで、この培養上清を、脱脂粉乳10重量%、グルタミン酸ソーダ1重量%を配合した分散媒と同量混合し、pH7に調整後、凍結乾燥を行った。得られた凍結乾燥物を60メッシュのフルイで整粒化し、凍結乾燥培養上清を製造した。表3に示した配合により原料を混合し、本発明のアディポネクチン分泌促進及び/又は減少抑制用イヌ飼育用飼料を製造した。
Claims (3)
- ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055 (FERM P-15535)の培養上清を有効成分とするアディポネクチン分泌促進及び/又は減少抑制剤。
- ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055 (FERM P-15535)の培養上清を有効成分とするアディポネクチン分泌促進及び/又は減少抑制用飲食品。
- ラクトバチラス・ガセリ(Lactobacillus gasseri)SBT2055 (FERM P-15535)の培養上清を有効成分とするアディポネクチン分泌促進及び/又は減少抑制用飼料。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007280195A JP5225652B2 (ja) | 2007-10-29 | 2007-10-29 | アディポネクチン分泌促進及び/又は減少抑制剤 |
CN2008801140967A CN101883571B (zh) | 2007-10-29 | 2008-10-28 | 脂联素分泌促进和/或降低抑制剂 |
EP08845900.3A EP2210609B1 (en) | 2007-10-29 | 2008-10-28 | Agent for promoting the secretion of adiponectin and/or inhibiting the decrease in the secretion of adiponectin |
ES08845900T ES2434691T3 (es) | 2007-10-29 | 2008-10-28 | Agente para promover la secreción de adiponectina y/o inhibir la disminución en la secreción de adiponectina |
PCT/JP2008/069568 WO2009057604A1 (ja) | 2007-10-29 | 2008-10-28 | アディポネクチン分泌促進及び/又は減少抑制剤 |
KR1020107011532A KR101515253B1 (ko) | 2007-10-29 | 2008-10-28 | 아디포넥틴 분비 촉진 및/또는 감소 억제제 |
US12/740,162 US20100278794A1 (en) | 2007-10-29 | 2008-10-28 | Agent for promoting the secretion of and/or suppressing decrease of adiponectin |
AU2008319923A AU2008319923B2 (en) | 2007-10-29 | 2008-10-28 | Agent for promoting the secretion of adiponectin and/or inhibiting the decrease in the secretion of adiponectin |
NZ584734A NZ584734A (en) | 2007-10-29 | 2008-10-28 | Culture supernatent ( or adiponectin promting agent) from Lactobacillus gasseri SBT2055 in manufacture of medicament for treating metaboblic syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007280195A JP5225652B2 (ja) | 2007-10-29 | 2007-10-29 | アディポネクチン分泌促進及び/又は減少抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009107956A true JP2009107956A (ja) | 2009-05-21 |
JP5225652B2 JP5225652B2 (ja) | 2013-07-03 |
Family
ID=40590994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007280195A Active JP5225652B2 (ja) | 2007-10-29 | 2007-10-29 | アディポネクチン分泌促進及び/又は減少抑制剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100278794A1 (ja) |
EP (1) | EP2210609B1 (ja) |
JP (1) | JP5225652B2 (ja) |
KR (1) | KR101515253B1 (ja) |
CN (1) | CN101883571B (ja) |
ES (1) | ES2434691T3 (ja) |
NZ (1) | NZ584734A (ja) |
WO (1) | WO2009057604A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009220403B2 (en) | 2008-03-07 | 2015-02-26 | Megmilk Snow Brand Co., Ltd. | Agents for promoting secretion and/or suppressing decrease of adiponectin |
CN105029104A (zh) * | 2015-08-28 | 2015-11-11 | 青岛大信饲料有限公司 | 一种专用于强化育肥猪的饲料 |
CN111281894B (zh) * | 2018-12-07 | 2022-03-25 | 深圳华大生命科学研究院 | 加氏乳杆菌在预防和/或治疗代谢性疾病中的用途和组合物 |
CN110628668B (zh) * | 2019-09-03 | 2021-03-30 | 北京量化健康科技有限公司 | 具有防治高血脂症功能的格氏乳杆菌以及产品组合物及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003252770A (ja) * | 2002-02-28 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 糖尿病合併症予防・改善・治療剤 |
JP2003306436A (ja) * | 2002-02-15 | 2003-10-28 | Snow Brand Milk Prod Co Ltd | 血清コレステロール上昇抑制剤 |
WO2007043933A1 (en) * | 2005-10-07 | 2007-04-19 | Arla Foods Amba | Probiotics to influence fat metabolism and obesity |
JP2007153741A (ja) * | 2005-11-30 | 2007-06-21 | Snow Brand Milk Prod Co Ltd | 腎周囲脂肪蓄積抑制剤 |
JP2008063289A (ja) * | 2006-09-08 | 2008-03-21 | Snow Brand Milk Prod Co Ltd | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 |
JP2008214253A (ja) * | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | 内臓脂肪減少剤 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2764267B2 (ja) * | 1988-04-20 | 1998-06-11 | 雪印乳業株式会社 | 胆汁酸分泌促進作用を有する機能性飲食品 |
JPH06319447A (ja) | 1993-04-14 | 1994-11-22 | Houki Rakunou Shoji Kk | 牛乳からアルコール飲料を製造する方法 |
JP3004890B2 (ja) | 1995-03-28 | 2000-01-31 | 雪印乳業株式会社 | 病原体感染防御剤 |
AU3843200A (en) * | 1999-04-27 | 2000-11-10 | Kabushiki Kaisha Yakult Honsha | Conjugated fatty acid esters |
EP1260227A1 (en) * | 2001-05-23 | 2002-11-27 | Societe Des Produits Nestle S.A. | Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria |
JP4853986B2 (ja) | 2001-09-20 | 2012-01-11 | 雪印メグミルク株式会社 | 炎症性腸疾患及び過敏性腸症候群の予防・治療剤 |
JP2003252772A (ja) * | 2002-03-04 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 加齢に伴う代謝異常症の予防・改善・治療剤 |
JP2004315477A (ja) | 2003-04-18 | 2004-11-11 | Tokyoto Koreisha Kenkyu Fukushi Shinko Zaidan | 骨吸収抑制剤 |
JP4846990B2 (ja) | 2003-08-06 | 2011-12-28 | 株式会社テラ・ブレインズ | アディポネクチン分泌促進剤 |
JP2005060308A (ja) | 2003-08-13 | 2005-03-10 | National Institute Of Advanced Industrial & Technology | アディポネクチンの産生増強、促進剤 |
JP5095912B2 (ja) | 2004-09-06 | 2012-12-12 | 雪印メグミルク株式会社 | 免疫増強剤 |
JP2006131512A (ja) | 2004-11-02 | 2006-05-25 | Pharma Foods International Co Ltd | アディポネクチン分泌促進組成物および該組成物を含有する飲食品 |
JP2006193502A (ja) | 2004-12-17 | 2006-07-27 | Asahi Breweries Ltd | アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬 |
JP2006193501A (ja) | 2004-12-17 | 2006-07-27 | Asahi Breweries Ltd | アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬 |
JP2006306866A (ja) * | 2005-03-31 | 2006-11-09 | Saga Univ | アディポネクチン上昇剤 |
CN101257914B (zh) * | 2005-09-05 | 2013-05-08 | 筑野食品工业株式会社 | 体内脂质改善组合物 |
JP4870469B2 (ja) | 2006-02-24 | 2012-02-08 | 雪印メグミルク株式会社 | ペプチド |
CN101678051B (zh) * | 2006-09-04 | 2012-12-12 | 雪印惠乳业株式会社 | 促进血中脂连蛋白浓度增加及/或抑制其减少的制剂及内脏脂肪蓄积抑制剂 |
JP5201832B2 (ja) * | 2006-12-25 | 2013-06-05 | 花王株式会社 | 脂肪分解促進用皮膚外用剤 |
-
2007
- 2007-10-29 JP JP2007280195A patent/JP5225652B2/ja active Active
-
2008
- 2008-10-28 WO PCT/JP2008/069568 patent/WO2009057604A1/ja active Application Filing
- 2008-10-28 KR KR1020107011532A patent/KR101515253B1/ko active IP Right Grant
- 2008-10-28 NZ NZ584734A patent/NZ584734A/xx unknown
- 2008-10-28 CN CN2008801140967A patent/CN101883571B/zh active Active
- 2008-10-28 US US12/740,162 patent/US20100278794A1/en not_active Abandoned
- 2008-10-28 EP EP08845900.3A patent/EP2210609B1/en active Active
- 2008-10-28 ES ES08845900T patent/ES2434691T3/es active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003306436A (ja) * | 2002-02-15 | 2003-10-28 | Snow Brand Milk Prod Co Ltd | 血清コレステロール上昇抑制剤 |
JP2003252770A (ja) * | 2002-02-28 | 2003-09-10 | Snow Brand Milk Prod Co Ltd | 糖尿病合併症予防・改善・治療剤 |
WO2007043933A1 (en) * | 2005-10-07 | 2007-04-19 | Arla Foods Amba | Probiotics to influence fat metabolism and obesity |
JP2007153741A (ja) * | 2005-11-30 | 2007-06-21 | Snow Brand Milk Prod Co Ltd | 腎周囲脂肪蓄積抑制剤 |
JP2008063289A (ja) * | 2006-09-08 | 2008-03-21 | Snow Brand Milk Prod Co Ltd | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 |
JP2008214253A (ja) * | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | 内臓脂肪減少剤 |
Non-Patent Citations (1)
Title |
---|
伊勢田依子, ET AL.: "Lactobacillus gasseri(ガゼリ菌SP株)発酵乳の脂質代謝調節機構", 日本農芸化学会大会講演要旨集, vol. 2006, JPN6012021918, 5 March 2006 (2006-03-05), pages 135 - 2, ISSN: 0002476335 * |
Also Published As
Publication number | Publication date |
---|---|
US20100278794A1 (en) | 2010-11-04 |
EP2210609A1 (en) | 2010-07-28 |
WO2009057604A1 (ja) | 2009-05-07 |
CN101883571B (zh) | 2012-09-26 |
CN101883571A (zh) | 2010-11-10 |
EP2210609B1 (en) | 2013-10-23 |
EP2210609A4 (en) | 2011-04-13 |
KR101515253B1 (ko) | 2015-04-24 |
AU2008319923A1 (en) | 2009-05-07 |
ES2434691T3 (es) | 2013-12-17 |
NZ584734A (en) | 2012-08-31 |
KR20100100827A (ko) | 2010-09-15 |
JP5225652B2 (ja) | 2013-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2127660B1 (en) | Agent for reducing visceral fat | |
JP6039638B2 (ja) | アディポネクチン分泌促進及び/又は減少抑制剤 | |
US10335441B2 (en) | Oral composition containing bifidobacteria and cruciferous vegetable | |
CN101678051A (zh) | 促进血中脂连蛋白浓度增加及/或抑制其减少的制剂及内脏脂肪蓄积抑制剂 | |
JP5229977B2 (ja) | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
JP5225652B2 (ja) | アディポネクチン分泌促進及び/又は減少抑制剤 | |
Saleem et al. | Therapeutic potential of popular fermented dairy products and its benefits on human health | |
JP5089942B2 (ja) | 内臓脂肪蓄積抑制剤 | |
KR102037897B1 (ko) | 케피어 유래 유산균 및 포도씨 분말을 포함하는 비만의 예방 또는 치료용 조성물 | |
JP6894242B2 (ja) | 非アルコール性肝障害抑制剤 | |
JP2004315477A (ja) | 骨吸収抑制剤 | |
JP2012012321A (ja) | 血中可溶性細胞間接着因子濃度上昇抑制剤 | |
KR101973514B1 (ko) | 포도씨 분말을 포함하는 프리바이오틱스 | |
AU2015200625B2 (en) | Agents for promoting secretion and/or suppressing decrease of adiponectin | |
WO2011025019A1 (ja) | チオレドキシン誘導活性を有する乳酸菌ならびにチオレドキシンを介する生体傷害の予防および/または改善用の飲食品および医薬品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100929 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110728 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130204 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130307 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130313 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5225652 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160322 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |